
Hershey's chief executive has credited the spread of Ozempic and other weight-loss drugs for an 8% jump in sales of the company's Ice Breakers mints and gum, pointing to a side effect of the medication that the broader industry had not foreseen as a revenue driver.
Speaking on Hershey's pre-recorded Q1 2026 earnings call on 30 April 2026, CEO Kirk Tanner said the company was seeing 'strong demand' for breath-freshening products he attributed directly to what he called 'GLP-1 adoption.'